COMT, estrogen and hormone therapy: separating biology from hype

What the COMT enzyme does

Catechol-O-methyltransferase, or COMT, transfers a methyl group onto molecules that share a chemical structure called a catechol. MedlinePlus Genetics explains that COMT breaks down neurotransmitters such as dopamine and norepinephrine in the brain, especially in the prefrontal cortex, and that another form of the enzyme in the liver, kidneys and blood helps control levels of certain hormones.

Among those molecules are catechol estrogens, which form when the body breaks down estradiol. COMT converts some of them into methoxy forms that are more easily cleared. This is one of several routes the body uses to process estrogen, not the only one.

The Val158Met variant, or slow COMT

A common change in the COMT gene swaps one amino acid, valine, for another, methionine. MedlinePlus Genetics notes that this affects the enzyme's stability and activity. People with two methionine copies have the lowest enzyme activity, which is why online reports label it slow COMT.

The variant is common enough that carrying it is a normal part of human genetic diversity. Research has connected it to small differences in working memory and attention, and studies of links to psychiatric conditions have been mixed. The popular warrior versus worrier framing goes well beyond what the data show.

The estrogen-clearance theory

The idea goes like this: some estrogen metabolites, particularly the 4-hydroxy forms, can be converted into reactive compounds that may damage DNA if they are not neutralized. If slow COMT methylates them less efficiently, more might linger, which could in theory raise breast cancer risk or worsen symptoms on hormone therapy.

It is a reasonable hypothesis. But when researchers have looked for an actual association between COMT variants and breast cancer, results have been inconsistent, and a consistent, meaningful effect has not been established. Enzyme activity in a living person also depends on far more than one gene, including how much substrate is present, the supply of methyl donors, and the many other enzymes that process estrogen.

What actually guides hormone therapy decisions

The Menopause Society describes hormone therapy as a first-line treatment for bothersome hot flashes, with benefits most likely to outweigh risks when it is started within 10 years of menopause or before age 60. Decisions rest on your age, symptoms, personal and family history, preferences and individual risks such as blood clots, stroke and breast cancer. Women with a uterus need a progestogen alongside estrogen to protect the uterine lining.

In February 2026, the FDA approved labeling changes for several menopausal hormone therapy products that removed boxed warning statements about cardiovascular disease, breast cancer and probable dementia. That change does not mean hormone therapy is risk-free; it means risks are now discussed in a more individualized way. COMT genotype is not part of any of these frameworks.

Do supplements support COMT?

Many genetic report websites recommend magnesium, methyl donors, cruciferous vegetable extracts or other products to support slow COMT. There is no outcome evidence showing these supplements change breast cancer risk or improve how women feel on hormone therapy. Some can interact with medicines, so check with a clinician before starting them.

Why one gene rarely tells the whole story

Estrogen is processed through several pathways in the liver and other tissues, involving different enzymes, conjugation steps and excretion through bile and urine. COMT is one step in one branch. Other genes, your body weight, alcohol intake, medicines, gut bacteria and the dose and route of any hormone therapy all shape how much of each estrogen metabolite you have at a given time.

Because of this, a single variant can shift enzyme activity in a test tube without producing a meaningful difference in a person. That is the gap that consumer genetic reports tend to skip over.

What genotype can and cannot tell you

• It can tell you that you carry a common variant with somewhat lower enzyme activity in lab studies
• It cannot tell you how much estrogen you actually clear, or your personal cancer risk
• It cannot tell you whether you will tolerate hormone therapy
• It should not, on its own, rule hormone therapy in or out
• Personal and family history, a breast exam and screening mammograms remain far more informative for breast cancer risk

Measured metabolites versus genes

If you and your clinician want to look at estrogen metabolism, measuring what your body is actually doing is more informative than a genotype. A dried urine hormone test such as the DUTCH Test ($449 one-time) reports estrogen metabolites. Even so, these results add context; they do not override symptoms, history and the evidence behind hormone therapy.

How HealifyMD uses this information

If you bring a genetic report to a HealifyMD visit, a licensed clinician will look at it alongside your symptoms, history and lab results. Hormone therapy decisions follow established clinical guidance. The Methylation Health Panel ($549 one-time) focuses on measured markers such as homocysteine, folate and B12, with MTHFR variants as context. Prices are confirmed at your eligibility review.